Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutex Health Inc. filings document the reporting obligations of a healthcare services and operations company with hospital, population health management and real estate-related activities. Recent Form 8-K reports furnish operating and financial results, including revenue, hospital division performance, earnings measures and cash flow, and disclose other corporate events tied to registration statements and auditor consents.
Proxy and annual-meeting filings cover board elections, advisory executive compensation votes, auditor ratification, common stock voting results and related governance disclosures. These documents also frame the company's capital actions, including common stock repurchase authorizations, within its public-company reporting record.
Nutex Health Inc. filed an amended Q1 2025 report to restate its financial statements and internal control conclusions. The company reclassified $20.7 million of non‑cash stock‑based compensation obligations tied to under‑construction and ramping hospitals from equity to liabilities, and made additional reclassifications including $3.5 million of related‑party payables to equity, $2.9 million from cash to restricted short‑term investments, and a $2.4 million income tax accrual adjustment. As a result, total liabilities as of March 31 2025 increased by $19.6 million (4.0%), equity decreased by $19.6 million (7.1%), and net income for the quarter rose by $6.6 million (14.9%) to $50.8 million. Basic earnings per share increased to $3.74 and diluted earnings per share to $3.33. The company states these changes are non‑cash and did not materially affect revenue, liquidity, debt, operating cash flow, adjusted EBITDA or patient volumes. Management concluded a previously identified material weakness in internal control over financial reporting remains unresolved as of March 31 2025, and has engaged an accounting firm to help remediate it.
Nutex Health Inc. filed a current report to announce that it has released its financial and operating results for the fourth quarter and full year ended December 31, 2024. The results are provided in a press release dated November 18, 2025, which is furnished as Exhibit 99.1 to this report. The company also clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Nutex Health Inc. filed an amended Annual Report on Form 10-K/A to restate its consolidated financial statements for the year ended December 31, 2024 and update related disclosures. The restatement primarily reclassifies $16.4 million of non‑cash stock‑based compensation obligations for under‑construction and ramping hospitals from equity to liabilities, in line with ASC 718 and ASC 480, and incorporates several immaterial reclassifications. As a result, total liabilities at December 31, 2024 increased by $13.4 million (2.9%), total equity decreased by $13.4 million (6.6%), and net income for 2024 declined by about $0.5 million (0.5%). Diluted earnings per share decreased by $0.02 to $9.69, and basic earnings per share decreased by $0.02 to $10.23. The company reports that these non‑cash adjustments did not materially affect revenue, liquidity, debt levels, operating cash flow, adjusted EBITDA or patient volumes, but it has identified an additional material weakness in internal control over financial reporting and has engaged external advisors to help remediate its control environment.
Nutex Health Inc. filed a Form 12b-25 to notify that its Quarterly Report on Form 10-Q for the period ended September 30, 2025 will be filed late. The company says it cannot meet the deadline without unreasonable effort and expense because it must first complete and file previously announced restatements of its 2024 Form 10-K and March 31, 2025 Form 10-Q, as well as the delayed June 30, 2025 Form 10-Q. Nutex Health received a Nasdaq notice on August 20, 2025 for not timely filing the June 30, 2025 Form 10-Q and obtained an extension to December 12, 2025, after which Nasdaq staff may issue a delisting notice if the report is still outstanding. The company also indicates that a significant change in results of operations versus the prior year is expected, with details referenced in an earlier Form 8-K, and it cautions that there is no assurance on the exact timing of the delayed filings.
Nutex Health (NUTX) filed a Form 3 for its Chief Operating Officer, Wesley Shane Bamburg. The filing states that no securities are beneficially owned by the reporting person as of the event date.
The event date is 10/15/2025, and the form was filed by one reporting person. This is a routine Section 16 initial ownership report confirming no current holdings.
Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.
The company also updated its Nasdaq listing status. Nutex is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to not timely filing its Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The company submitted a compliance plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025 to file the June 30, 2025 Form 10‑Q by December 12, 2025. If Nutex does not file by December 12, 2025, Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.
Nutex Health, Inc. appointed Michael Bamburg as Chief Operating Officer and disclosed the principal terms of his employment agreement dated September 16, 2025. Bamburg, age 43, joins from HCA Houston Healthcare with a background in payor contracting and provider operations and holds a B.S. in Healthcare Administration and an MBA. The two-year agreement provides a base salary of $415,000 with automatic two-year extensions unless timely notice is given, eligibility for an annual cash bonus up to 60% of base salary, participation in long-term incentive awards valued up to 60% of base salary if granted, and a $100,000 signing bonus payable over four quarters if he remains employed at least 12 months. The agreement includes twelve months' severance and health subsidy if terminated without cause or for good reason, and standard accrual and reimbursement provisions. The filing incorporates the full agreement as Exhibit 10.1.
Nutex Health, Inc. appointed Michael L. Reed as Lead Independent Director effective September 2, 2025. Mr. Reed has been a director since April 2022 and serves on the Audit, Compensation, and Nominating and Corporate Governance Committees. In the new role he will preside over executive sessions of independent directors, facilitate communication between independent directors and the Chairman/CEO, and act as a liaison between the Board and management, consistent with the company’s governance guidelines and Nasdaq Listing Rule 5605. The appointment carries additional compensation under the company’s existing director compensation program disclosed in the proxy filed June 2, 2025.
Nutex Health Inc. reports that a putative securities class action was filed on August 22, 2025 in the U.S. District Court for the Southern District of Texas, captioned Anjana Bhagavan v. Nutex Health Inc. (Case No. 4:25-cv-03999).
The complaint names the company, its Chairman and Chief Executive Officer, its Chief Financial Officer, and its President and Director as defendants and asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The allegations track a recent short seller report, and the plaintiff seeks unspecified damages.
Nutex Health disputes the allegations and intends to vigorously defend the lawsuit. The company states it cannot predict the outcome or estimate the financial impact, but acknowledges that an adverse ruling could have a material adverse effect on its financial position or results of operations.